Forest Laboratories, Inc. (FRX) Misses Q3 EPS by 7c; Eases FY13 Outlook
Tweet
Share
E-mailGet Alerts FRX Hot Sheet
Price: $12.00 --0%
Financial Fact:
Diluted (in shares): -539.2M
Today's EPS Names:
OFLX, NMRD, VAXX, More
Financial Fact:
Diluted (in shares): -539.2M
Today's EPS Names:
OFLX, NMRD, VAXX, More
Join SI Premium – FREE
Forest Laboratories, Inc. (NYSE: FRX) reported Q3 EPS of ($0.21), $0.07 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $678 million versus the consensus estimate of $765.94 million.
The Company now expects that non-GAAP earnings per share for the fiscal year ending March 31, 2013 will be at the lower end of the previously guided range of $0.45 to $0.60. Total net revenue (includes product sales as well as the earnings contribution from Benicar, authorized generic sales of Lexapro, interest income and other income) is now expected to be between $3.1 billion and $3.2 billion.
For earnings history and earnings-related data on Forest Laboratories, Inc. (FRX) click here.
The Company now expects that non-GAAP earnings per share for the fiscal year ending March 31, 2013 will be at the lower end of the previously guided range of $0.45 to $0.60. Total net revenue (includes product sales as well as the earnings contribution from Benicar, authorized generic sales of Lexapro, interest income and other income) is now expected to be between $3.1 billion and $3.2 billion.
For earnings history and earnings-related data on Forest Laboratories, Inc. (FRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Globant (GLOB) Misses Q2 EPS by 10c, Offers Guidance
- NextNRG, Inc. (NXXT) Tops Q2 EPS by 4c
- Xos, Inc (XOS) Tops Q2 EPS by 5c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
